# Kisspeptin Dosage in Research: Doses, Routes, Half-Life and Tachyphylaxis

> Kisspeptin dosage as studied in research: the IV, subcutaneous and intranasal protocols by population and route, the kisspeptin half life, and why tachyphylaxis limits continuous dosing.

Every dose here is reported as what was administered to which population by which route. None is a human dosing recommendation.

## The short version

There is no standard kisspeptin dosage, because kisspeptin is not an approved medicine and there is no clinical dosing protocol — every number in the literature is a research dose given to volunteers or patients under medical supervision. This page reports those doses strictly as "studied at X in [population] by [route]." It does not tell anyone what to take, and it never will.

Two facts shape every protocol. First, the two research forms clear the body at very different speeds: kisspeptin-10 has a functional half-life of only about 4 minutes, while kisspeptin-54 lasts roughly 27 to 28 minutes [8]. Second — and this is the one that matters most — the receptor desensitizes. Continuous or frequent dosing makes the response shrink, an effect called tachyphylaxis, so more is not better and steady infusion tends to fade [4][16]. Routes studied include intravenous bolus, continuous IV infusion, subcutaneous injection and, since 2025, an intranasal spray [6].

## Kisspeptin dosage as studied, by population and route

The doses below are the research protocols on record. They are not interchangeable, not scaled to body weight for self-use, and not recommendations.

- **Healthy men, intravenous kisspeptin-54:** 4 pmol/kg/min infused over 90 minutes (the early human characterization) [8].
- **Healthy men, intravenous kisspeptin-10:** 0.3–1.0 µg/kg as a bolus; 1.5 µg/kg/h as a continuous infusion, with a higher 4 µg/kg/h infusion used to move testosterone [3].
- **Women with hypothalamic amenorrhea, intravenous kisspeptin-54:** 0.01–1.00 nmol/kg/h by continuous infusion, where the highest rate produced tachyphylaxis [4].
- **IVF patients at high OHSS risk, subcutaneous kisspeptin-54:** a single bolus of 3.2, 6.4, 9.6 or 12.8 nmol/kg as an oocyte-maturation trigger, with the best live-birth rate near 9.6 nmol/kg [5].
- **Intranasal kisspeptin-54:** a primary dose of 12.8 nmol/kg in the 2025 nasal-spray study (with 3.2/6.4/25.6 nmol/kg also tested in men) [6].

The through-line: the form, the route and the population all change the dose, and none of these maps onto any consumer use.

## Kisspeptin half life

The kisspeptin half life depends entirely on which form is studied. Kisspeptin-10 is cleared fast — roughly 4 minutes in humans — because plasma peptidases chew through the short fragment quickly. Kisspeptin-54 is far more durable, with a measured plasma half-life of 27.6 ± 1.1 minutes [8]; its larger size and greater resistance to endopeptidase cleavage give it a substantially longer duration of action. That difference is why kisspeptin-54 dominates the reproductive-medicine studies (where a sustained signal helps) while kisspeptin-10 suits acute pulse-frequency experiments. The short half-life of kisspeptin-10 also means receptor sensitivity may be better preserved with well-spaced or pulsatile exposure than with continuous infusion.

## Kisspeptin nasal spray

Until recently, kisspeptin meant an injection or infusion. The kisspeptin nasal spray changed that. In 2025, intranasal kisspeptin-54 at a 12.8 nmol/kg primary dose rapidly stimulated LH release in healthy men (+4.4 IU/L), healthy women (+1.4 IU/L) and women with hypothalamic amenorrhea (+4.4 IU/L), with no adverse events — and the nasal-spray formulation was stable for up to 60 days at 4 °C [6]. That is the first clinical demonstration of an effective non-invasive route. It remains a research formulation studied in supervised settings, not a marketed product; the result is reported here as the route's proof of concept, not as a usable protocol.

## Why tachyphylaxis is the central dosing problem

Tachyphylaxis — a fast fall in response with repeated dosing — is the defining limitation of kisspeptin pharmacology, and it shapes any dosing schedule the literature describes. Chronic twice-daily subcutaneous kisspeptin-54 in women with hypothalamic amenorrhea caused the acute LH increment to collapse from about 24 IU/L on day 1 to roughly 2.5 IU/L by the 14th injection day [16]. High-dose continuous IV infusion likewise desensitized the axis during the infusion [4]. The practical implication, drawn straight from the data: continuous or escalating exposure tends to defeat itself, and well-spaced or pulsatile delivery preserves the response better. This is a finding about the receptor, not advice about a regimen.

---

A data-forward monograph of the kisspeptin literature — every endocrine readout logged to its study, population and route, with the tachyphylaxis ceiling and the investigational status kept in plain view; no clinic behind the page and nothing here dosed, prescribed, or sold.